insulin icodec + insulin aspart

**Insulin icodec + insulin aspart** is a combination insulin regimen under clinical development for the treatment of diabetes mellitus, specifically type 1 and type 2 diabetes. It consists of **insulin icodec**, a novel ultra-long-acting basal insulin analog administered once-weekly by subcutaneous injection to maintain basal insulin levels, and **insulin aspart**, a rapid-acting insulin analog administered 2-4 times daily before meals to control prandial (mealtime) blood glucose spikes[2][4]. The regimen aims to provide both sustained basal insulin coverage and flexible prandial glucose control. The mechanism of action for both components is binding to and activating the insulin receptor, thereby increasing peripheral glucose uptake and suppressing hepatic glucose production. Developed by Novo Nordisk, this combination is intended to improve convenience, adherence, and overall glycemic control compared to current standard multi-injection therapies[2][3][4].